Changes in soluble fibrin levels during the perioperative period of gynecologic cancer surgery
- Authors:
- Junichi Kodama
- Noriko Seki
- Chikako Fukushima
- Tomoyuki Kusumoto
- Keiichiro Nakamura
- Atsushi Hongo
- Yuji Hiramatsu
View Affiliations
Affiliations: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
- Published online on: August 31, 2012 https://doi.org/10.3892/ol.2012.891
-
Pages:
1122-1124
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The purpose of this study was to evaluate the changes in plasma soluble fibrin (SF) levels over time in gynecologic cancer patients following surgery. Furthermore, we examined the duration of the coagulation stage and determined a suitable duration for which thromboprophylaxis with anticoagulant agents should be administered. We retrospectively studied 311 patients with invasive gynecologic cancer who underwent surgery at Okayama University Hospital, Japan. The plasma SF levels were measured serially prior to the operation and on postoperative days 0, 1, 3, 5, 7, 10, 14, 21 and 28. The plasma SF levels increased rapidly, peaked on postoperative day 1 and then decreased. The SF levels of patients with venous thromboembolism (VTE) were significantly different from those of VTE-negative patients on postoperative days 0-10. The SF levels on each day did not significantly differ between patients treated with chemical anticoagulants and those treated mechanically. The plasma SF levels were elevated (≥7.0 µg/ml) in 159 of the 311 patients (51.1%) on one of the days when these levels were measured. Among the patients with elevated plasma SF levels, 110 patients (69.2%) peaked on days 0-3 and only 9 patients (5.7%) peaked on days 21-28. Although only 1 of the 14 patients (7.1%) who showed peak levels on day 14 had undergone chemotherapy following surgery, 8 of the 9 patients (88.9%) whose levels peaked on days 21-28 had undergone chemotherapy following surgery (P=0.0002). In conclusion, the plasma SF levels increased rapidly, peaked on postoperative day 1 and then decreased. These levels peaked within 14 days of surgery in most cases. Therefore, chemical thromboprophylaxis may be administered for at least up to 14 days following surgery.
View References
|
1.
|
A LinJ RyuD HarveyLow-dose warfarin does
not decrease the rate of thrombosis in patients with cervix and
vulvo-vaginal cancer treated with chemotherapy, radiation, and
erythropoietinGynecol
Oncol10298102200610.1016/j.ygyno.2005.11.03116406065
|
|
2.
|
CT BradleyKJ BraselJJ
MillerCost-effectiveness of prolonged thromboprophylaxis after
cancer surgeryAnn Surg
Oncol173139201010.1245/s10434-009-0671-619707830
|
|
3.
|
MH EinsteinEA PrittsEM HartenbachVenous
thromboembolism prevention in gynecologic cancer surgery: a
sysytematic reviewGynecol
Oncol105813819200710.1016/j.ygyno.2007.03.00417449089
|
|
4.
|
A SuzukiH EbinumaM MatsuoThe monoclonal
antibody that recognizes an epitope in the C-terminal region of the
fibrinogen alpha-chain reacts with soluble fibrin and fibrin
monomer generated by thrombin but no with those formed as plasmin
degradation productsThromb
Res121377385200710.1016/j.thromres.2007.05.008
|
|
5.
|
A TsujiH WadaT MatsumotoElevated levels of
soluble fibrin in patients with venous thromboembolismInt J
Haematol88448453200810.1007/s12185-008-0173-518836793
|
|
6.
|
J KodamaN SekiS MasahiroD-dimer level as a
risk factor for postoperative venous thromboembolism in Japanese
women with gynecologic cancerAnn
Oncol2116511656201010.1093/annonc/mdq01220129998
|
|
7.
|
G SoeI KohnoK InuzukaA monoclonal antibody
that recognizes a neo-antigen exposed in the E domain of fibrin
monomer complexed with fibrinogen or its derivatives: its
application to the measurement of soluble fibrin in
plasmaBlood882109211719968822930
|
|
8.
|
H BounameauxP CiraficiP de
MoerlooseMeasurement of D-dimer in plasma diagnostic aid in
suspected pulmonary
embolismLancet337196200199110.1016/0140-6736(91)92158-X1670841
|
|
9.
|
T MisakiI KitajimaT KabataChanges of the
soluble fibrin monomer complex level during the perioperative
period of hip replacement surgeryJ Orthop
Sci13419424200810.1007/s00776-008-1266-y18843455
|
|
10.
|
A SudoH WadaT NoboriCut-off values of
D-dimer and soluble fibrin for prediction of deep vein thrombosis
after orthopaedic surgeryInt J
Hematol89572576200910.1007/s12185-009-0323-419430861
|
|
11.
|
C KearonDuration of venous thromboembolism
prophylaxis after
surgeryChest124386S392S200310.1378/chest.124.6_suppl.386S14668422
|
|
12.
|
D BergqvistG AgnelliAT CohenDuration of
prophylaxis against venous thromboembolism with enoxaparin after
surgery for cancerN Engl J
Meed346975980200310.1056/NEJMoa01238511919306
|
|
13.
|
EA AklI TerrenatoM BarbaExtended
perioperative thromboprophylaxis in patients with cancerThromb
Haemost10011761180200819132245
|
|
14.
|
A PeedicayilA WeaverX LiIncidence and
timing of venous thromboembolism after surgery for gynecological
cancerGynecol
Oncol1216469201110.1016/j.ygyno.2010.11.03821183211
|
